UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to
Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
February 20,
2007
CYCLACEL
PHARMACEUTICALS, INC.
(Exact name of registrant
as specified in its charter)
|
|
|
|
|
|
|
| Delaware |
|
|
0-50626 |
|
|
91-1707622 |
(State
or other jurisdiction
of incorporation) |
|
|
(Commission File
Number) |
|
|
(IRS Employer
Identification
No.) |
|
200 Connell Drive, Suite 1500
Berkeley
Heights, NJ 07922
(Address of principal executive offices and zip
code)
Registrant’s telephone number, including area
code: (973)
847-5955
(Former
Name or Former Address, if Changed Since Last
Report)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing
obligation of the registrant under any of the following provisions
(see General Instruction A.2. below):
|
|
![[ ]](https://cdn.kscope.io/b291ce05223dd343bb1631c1d17251f6-ebox.gif) |
Written communications pursuant
to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
| |
Soliciting material pursuant to
Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
| |
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b)) |
|
|
| |
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c)) |
ITEM 8.01 Other Events.
On
February 20, 2007, the Company issued a press release
announcing the completion of its previously announced registered direct
offering on February 16, 2007 resulting in gross proceeds of $36
million through the sale of 4,249,668 shares of common stock and
warrants to purchase 1,062,412 shares of common stock. As a result of
the issuance, there are 20,407,621 shares of common stock outstanding.
A copy of the press release is attached hereto as Exhibits 99.1
and incorporated herein by reference.
Neither the filing of the
press release as an exhibit to this report nor the inclusion in the
press release of a reference to our internet address shall, under any
circumstances, be deemed to incorporate the information available at
our internet address into this report. The information available at our
internet address is not part of this report or any other report filed
by us with the SEC.
Item 9.01 Financial
Statements and
Exhibits.
|
|
| (c) |
Exhibits: |
|
|
|
|
| No. |
|
|
Description |
| 99.1 |
|
|
Press Release dated February 20,
2007 |
|
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
| |
|
|
CYCLACEL PHARMACEUTICALS,
INC. |
| Dated: February 20,
2007 |
|
|
|
|
|
|
|
|
|
| |
|
|
By: |
|
|
/s/ Paul
McBarron |
| |
|
|
|
|
|
Name: |
|
|
Paul
McBarron |
| |
|
|
|
|
|
Title: |
|
|
Executive
Vice President, Finance & Chief Operating
Office |
|
Exhibit Index:
|
|
|
|
| No. |
|
|
Description |
| 99.1 |
|
|
Press Release dated
February 20,
2007 |
|
CYCLACEL
PHARMACEUTICALS COMPLETES $36 MILLION REGISTERED DIRECT
FINANCING
BERKELEY HEIGHTS, NJ, FEBRUARY 20,
2007 — Cyclacel Pharmaceuticals, Inc. (NASDAQ:
CYCC, NASDAQ: CYCCP) announced today that it has completed its
previously announced registered direct offering through the sale of
shares of its common stock and warrants for gross proceeds of
$36 million, before deducting placement agent fees and estimated
offering expenses. The purchase price for the shares and the exercise
price for the warrants was $8.44 per share, the closing bid price for
the Company’s common stock on February 12, 2007.
Investors in the financing paid $0.03125 per warrant, for an aggregate
purchase price of $8.47125 for one share of common stock and a warrant
to purchase 0.25 of a share of common stock. At closing, the Company
issued approximately 4.2 million shares of common stock and
warrants to purchase approximately 1.1 million shares of common
stock. The shares were offered under the Company’s effective
shelf registration statement previously filed with the Securities and
Exchange Commission.
Lazard Capital Markets LLC served as
lead placement agent and Needham & Company, LLC and ThinkEquity
Partners LLC served as co-placement agents for the
offering.
This press release shall not constitute an offer
to sell or the solicitation of an offer to buy nor shall there be any
sale of these securities in any jurisdiction in which such offer,
solicitation or sale would be unlawful prior to the registration or
qualification under the securities laws of any such jurisdiction. Any
offer will be made only by means of a prospectus, including a
prospectus supplement, forming a part of the effective registration
statement. Copies of the final prospectus supplement together with the
accompanying prospectus can be obtained at the SEC’s website at
http://www.sec.gov or from Lazard Capital Markets LLC at 30 Rockefeller
Plaza, 60th Floor, New York, NY, 10020.
About
Cyclacel Pharmaceuticals, Inc.
Cyclacel is a
development-stage biopharmaceutical company dedicated to the discovery,
development and commercialization of novel, mechanism-targeted drugs to
treat human cancers and other serious disorders. The Company is
currently evaluating seliciclib (CYC202), an orally-available cyclin
dependent kinase inhibitor, in Phase IIb clinical trials for the
treatment of lung cancer. Sapacitabine (CYC682) is an orally-available,
cell cycle modulating nucleoside analog is in Phase I clinical trials
for the treatment of cancer. An IND was submitted in December
2006 for CYC116, an orally-available, Aurora kinase and VEGFR2
inhibitor. Several additional programs are at an earlier
stage.
Note: The Cyclacel logo and Cyclacel® are
trademarks of Cyclacel Pharmaceuticals,
Inc.
|
|
|
|
| Contacts
for
Cyclacel: |
|
|
|
| |
|
|
|
| For
Investors: |
|
|
|
| TS Communications Group,
LLC |
|
|
(914) 921-5900 |
| Tara Spiess/Andrea
Romstad |
|
|
|
| |
|
|
|
| For
Media: |
|
|
|
| Feinstein Kean
Healthcare |
|
|
(617)577-8110 |
| Robert
Gottlieb/Kate
Weiss |
|
|
|
|
![[X]](https://cdn.kscope.io/b291ce05223dd343bb1631c1d17251f6-cbox.gif)
200
Connell Drive, Suite 1500, Berkeley Heights, NJ 07922 USA T:
+1 (908) 517 7330 F: +1 (866) 271 3466
Dundee
Technopole, James Lindsay Place, Dundee, DD1 5JJ,
UK Tel +44 1382 206 062 Fax +44 1382 206
067
www.cyclacel.com
–
info@cyclacel.com
begin 644 html_04897logo.jpg
M_]C_X``02D9)1@`!`0$!(`$@``#__@`V($EM86=E(&=E;F5R871E9"!B>2!'
M3E4@1VAO``$``@$%`0$``````````````P<(`00%!@D""O_$`$`0
M```&`@$!`PD&!`8"`@,```$"`P0%!@`'"!$2%5$)$Q17D9>QTM8A,4%28:$6
M%W'1(B,R@<'P"D(8-$."LO_$`!T!`0`#``(#`0`````````````!`@,&"`0'
M"07_Q``\$0`!`P(#!`4+!`$$`P`````!`@,1``0%$B$&$S%Q(D%1D?`'%%-4
M88&2H;'1TR,RU/$5"!9"P1;[_Q_TE^X1#[P
M_3_OA]OV9@CO[F.G3+%_*O2\";9FUUUC,%V[)N[E(>OON@=IFJVC#>ESG-E'OFV\
MC-M0$1!->/(Z;MV+A0HI(23YJX4`R394`PV:4]WIHKW1NEY:*C]J!6RV?DIR
M(DS"DVUQ6W)0D58N(D%CF5:'[!SKH)-3=YNNRB^6,24=+/H;WCY-=B<*?MK?
M:3:2U;Q!%TNZ5@6"W5R]98:];88MEG$]H]HKMA#ERU@&'W;S&'VMI9MNWV/8
MTXC"[5M92XASH_\`ZE/+=M588G?>3;R;XI<[//86SA2=NMM<+P^UQC:2TQ+:
M1A^\V:\G7D\PJ^?M\.N=O,?PJSOL?Q3%\7N+;!=A=C+9[:?$[ED%AZWJW8<1
MNVP&2<4-4U>NYZNTZ$>=,2F&E/H?I`J5'E]%M9='L&04L58VQ1&BJP*%$`+/)]\E0`IB^=!19N!>@
M$,8"@(F+=C&J5.!A0M%-INM&M6DEW*;;D)RVD';EQL.4[9%'4A0]9IE="JR5
M7(X49N7,-,/'2"@JO'1%^V`\$V.C87(Q,;*\/-KN'8I%0I[^@2&E+!).51_^
MG59]6$H!U7!1#H@9*Q)F(NVUJZU:/W%AA]H2BXL\'P#9
M7!\'M=VJ+AIRS5L_M$SA.3@[:[1[6X7B+!"TX@W8/(=2W\NMI=G[7$<3MKK%
MK"PV@Q_%D(N+'&-K=N?*CM=MAB8N&D+LKIC&&MO_`">WFU6_(S6F*>3SR2[4
M;/7R2RO9]_'K-VW"<%"N&*0]54_6#4NV*CN>EQUXISEP>->JKLW+-\0&
M\E$RK,$_3HF2;D4533>-?.IF$R"RS==!5!PW6416(.>.-=GDW-TM=:^1O?T&QQFU=!W1,])MSV[5ZT;`KF
MU6-MUNX@+06[W*>FV]/3J&P&5]EV%>9UZ0)&SL2@*A++UT\MKFQ"5V]O8X79
MV>UP6P_!6R,)L'+!UI:U-8U@R7KJU9Q0E5MT^/Z'=7T0K3H'Z^T?[XZ!^OM'^^:
MXQ)[3X_H=U*TZ!^OM'^^.@?K[1_OFN,2>T^/Z'=2M.@?K[1_OCH'Z^T?[YKC
M$GM/C^AW4K3H'Z^T?[XZ!^OM'^^:XQ)[3X_H=U*U)_J'[_N+^(C_`.WZY/D!
M/M,/]"_AX&Z_#[?Z9/@_]#Z"E,8QD4IC&,4IC&,4IC&,4IC&,4IC&,4IC&,4
MIC&,4IC&,4IC&,4IC&,4IC&,4IC&,4IC&,4IC&,4IC&,4IC&,4IC&,4IC&,4
MIC&,4K!>3*VLW-&>GY5/TJ&X^:-;2+5%0$@0;62XN9%\JZ`%"G'SQX!%<4W!
M0`4%$$Q`0$@=N@JQ`-Y;7].7NA7Z['9D;>>7/(,I2G%_;JO6G"#FCT$ZA5R>
M=C'BTK%@6.,5%N[:QCA-$"F6,`Y4-()/_P"26_H%0YDW.S-(T*5CCJ%$I#)1
MQ[72)$J*I2&+YMFNO$J+=1%0JC\!`@DZ#E>5.)5G==ZU2:-`],LO&>*X-97!._M6R/G!CVR+
MF+8ICC]Y;HO;_$MM_+OB%W8.M>=(Q"[_`/+6P>QF%,7EFF7+A.([`X5L?L2]
M;N$^<;+;98SAV46.)OMF77^J;-=;8^M$S(%@+2P1C4+?;D(B+DYJMR+R/8S<
M;J'3C>P,).OT6IT6!D8QK9+*TB7L]/V5PY2269K,G"R7.[23:@8BVHP68($5$".&YC]R7AHA>896!=BU5FHV/D8AA)G3`732-F'<6]D62*PF`"(
M/GD+$+KDZ=3K,&QBB42!GK?%=M]HK?&$O6[C5CYDVPU:LHL[-PVZ6FQN@TMU
MEQZW2RX5JL6T.A6$`H8L5,*MD%/9'9#R&^3K$-C%6V)6]WCQQIZ^N\5O'L:Q
MAD7SMU<$7/G3-K>6]EB"KIAMEK&KI^T4UM<4NWV--WS>(.H7Y>5/B+8>2MIX
M_P"Y=UR&TM6Z_P"-UXIVV^(NH8JVV_7^V8Z&G-3UF%OFO^=$46RW:F[-FF5W
M83)HF&JG3IT#H`!]@?H'
MW?T_#.OVUE*R58L,?!/0C9M_!S+*'D!66;`QE7<8[;QKT7+&65IA]A;M6EE86MO96=M;H#;-M:VK2&+>W8;2(;:99;0VVA(`2A
M"4C@*\K;+Y6RM6"_[#H7$?B%R_YUMM0VN;I&S]G\=:?K>/TC7+G4D@5NE%A-
MK[CV9K2N[%O=6[2;63KFO?XA)WHNC$(2BLB?TX]$
M[:<\?M<\EZ!!;I@*_7'.R];75%%M:V=9:1%DG5T[SI.T.6E.W'37O8>UB:>L
MW+%S+PR_>)?-SR#_`"8XVZYX":VXCWVX:_T3R@XA!?\`6G*;16S+I`5+9=9V
M=#WRT2MRV;-0]MD(J9EJSM1Q)#L6/O2"+R"?ISJS$907,2Y10WGE_P!-G%\`
M(KRB7'K83:I\B^']AHVP>+O("A+P5E1;5WD+9ZGHS8D.W=F&0@;5KW8.O]@]
MXKM$SKL'LQ7ZK-MESE8"5S4)!A(!))@*UCJ@@:<>&O49K53F1!<4L`)`6I(`
MT3$*G]Q@<=-9$216:TCY5WBS7XOF;?;;)62L:+X4;#@M+7;>SR+0DZ5LK>KU
MNW+9M,:3B(!S*W78E]HM@DH&DS\='UQ)-W=YI*`@5),T?+NF/+<=^>^R=\[.
MK=1F?)V<\-":]NC:?5K6Z-Z4K3];JJ"]?AN^S(7JGU_<5FVAK."V\^->A]JP^P)VP\B)1H+V?I,=7
MY"KZ.I$ILW7NFH7:.[7DK8(E[5M?36T-FUFH1LTR8R?GY`LMT)VHXR2N)W_C
MW[9UUFNXXU*F+W*MIVH\BOR-W*X18EK9Y,LT=VHV$')&Q
M&)EC-_\`.`@I@)@\QI9YO#RC$IY5;<$+Y.G>/*O1W->$E.#_`!5WK2-P\5*G
M5:IH#C#(W&JUZ]4R&WGN;7EU1>S?*MW;MX"_&O(5UR^@JB:-=/5X1ZLLRZF1
M`G2=!!,<21U:@SSGKD+E"87F5H%$0HY@!((`(S$G7HZ2>$:?J%Y7\N=*<,-4
MK;:W?8'\?$NI^*I5,JM8A7UNV1M38UB54;U76&J*%#D5GK[L.TN4E$(.M0R!
MUUBI.7KM5C&LW;U#&;5/E$+U>IB=_F%Y/'G;QZHC37M_V5`[,W%4-+MJW)0^
MNX=>7D(2SQ=,W1;K;K2Y3Z+=4M2KMW@6!IDZ:O;>,@(`G\()GF'+[7U?Y!WR
MA/*-!U%:]X<\HMT\>?**(2C)":8Z4Y2,]66#C;`;BV6];&=)5VOU?:<3_%LA
M._Y\+66U_B9165%1)@NX_2+MK?\`H38.AMFL*!NC4%T?W#0FWIZGM*?LFCV9
MU:8)AKR=7?S-:;04X_6G(ADBJDN\DHLCIBW1435773*J41!(E(()GCQTZ0'T
M]TD:]50IPPM04$Y4R$G+J%&?0%W-.960.Q,UGE%HX'+9.UO\`
MQ[]M:LK7#6_U*P[)H$%:GG//FRV:5J9NE9B[`Y7E-_2Z<8BWA7\HWDEU9%19
M)-@DBU.H\.JD5N1054^V*>("3P]IX$29X1[1(]O;#;G10I3J3F5$]$#5$A/;
MF!!(G*2#JGJ'LKJG3FR:3M38-VM.WYRZUBUKV-6`I;_SA(^I$E;0678(L``P
M>D%09`HFJK(G>KLW#I2-KRD-56[:&#*#("?ZA_H7]C]/^A]X?C]N3Y51).O8
MD<(T"0!\JV0@($"8)*M22949.IZIX#JZJ8QC*U:F,8Q2F,8Q2F,8Q2F,8Q2F
M,8Q2F,8Q2F,8Q2F,8Q2F,8Q2F<1/SL15X27LE@D6L1!0$7(3T,2R=:N->F
MZK8HXRBB17\%8XIW"S#(RJ)B+)@[CGSEN*B1BJ)^<[9![10Q2L&=9\_F%P:U
MV]7_`$)N#1O'S85!=[.UKR)V8MKXNN7]-1;PLA$O=FI5JXSL]H=Y>(2P1<_0
M(_:;"'/.LU5(*57KE[3+3E+[V)R_XP:FENX]D[YU;2YI>/&Q--U_0^G=306N]P]M/J'8+=7J.16-
MKJ--:Z3J\]L9VA?[)(PS!DSK+*MM&>3UY&4G6FCKNMO.L0?*B7TQL^B\J[=L
M363#<+>VS7(*[439MZL]?:,KA6:ZELBB2-(A:/"/IU&YZQL],.P(W5'>FQ8'7%PW,Z<-*3KF^340PN;Q13:%NU!6CNF<<[D6
M$>E?+U2YJ`H*K]^U3N$T@>`@#2$^V>1K?MP(!T-AN$>1>IW9=5RD;"7A-
MC;6#]U$RTS9'],B(]NR9"X>SSJ5ND3+TN-2K3>9%_<8>7JC7SM@BY".;>=3K
MR1^QA:ZOJ+;E2X=:XUZ]T9.$KTG4-ALDDYS27*^P\G%E8RKTG>%.UG**;&4G
M6M5EIS9E(V-.T!6(7F=9*P#6:"#A^;F_)9;2FM;:LUDZY&U<]=XL6*DRW%IK
M&ZGLE(E46=+<7Q@A_//86M]NU#:EJGW-%OCFK-Y34]UU'#L+/%I;0=UF;F)!
M6NLE*]&-8P\K2KA4]V&VF2LJU.48/W"
MSY5D;4\Z66.X;-6R:CM@BV6<+$D$F>`<9Y8>EQVIZANO;7&S=VG-=;5XYVKE
M#IFP66S:)L+?86M*3%T.R6@KE&F;3FWM!G(NF[$@[>H2^,H2!&+:S#!:P-K"
MV8P\GD-PWX*I<3QO#E.\Q5B9
MU=K:YW?[XY&,[8)F?;G@CR<];+--6!^]0INF>2(X^ZZX4&XN4*O:OJ&SICCM
M2-!7KDG`:;@(^Z7MM6#51Y.S4\T0DRS#AA<)VKI3\K6%[BY9'E%D';QU(N&"
M"XJ5E5(^4!X6Q%-8;`D>3.GVM1DK)<:FUEU+@P$H3>O$VCF_-G;)+SDE&H4>
M.D8J9N$C),FD56(&8A9Z[+!O9[4.2RU$K/(:?W3(7&HJU;82$;');=X[\?\`0K:7%UJ_=>J9:]2U
M+0T?(2S.H[`DIC4%F;W]=&R:^+"
M2ADCR2[H>*TIQG3I8`:RO!9J(%D4[:A:3>E*I(M$ZZG#D()91)2KQC>?_"V:
MKEGML%R[2+?ZD(A>(5P%Y8SDVE5H-Y#
MJ(.%$BMINVKH4V&7D%&*4K=%4ZZA4=-P^L^2RE;F-3:2
MXVZ4>J-J?ROT+H6Y;GMC\TE8=6;:HVT*8SMSK;C9Z5O0+[!2C.0IC9A-3
M5FJ-HL=<<;[2ODQ=H:$@JO4J/R0JRT'-4*G:NWE(SFBBS=AL50U_R.WGO^!<
M:G4LNR++%Z_LDJUW].1]Q*:,K%TA[=?&[+6TJZ"-L=485L&.PN1\UQ<59,[
M--3C"-DK=4]I5R1XMNJ8&NDJV]::K<
M=)AQ[CN.]DL&O-LVM)E7N/FRU;[&PVUV5QY&68SV-N,<="`FJYI1735.B;`@
MZV%$5\SZ13KD78--\E7K9!O((VN2;H-JO.C?2I*T.)]Y4KSL.YU[L.O[UC-MSM;6H
MDI$NY!Y-IPM;TS;;1:7Y6"47#5I(9YP])%1TTZC<6F/D[.2<5KO3NM6'+"JL
MJKQY::IH>M8>M:?MVLGEMU1JVM7BJ1S/;NR=4[JINZ7=RK_`,813]I.U]6"_B2.DX1XTDF,Q#J1G>[-]$OVZRC%\TD&(IN(]X@X.T=(
MK(KI+&04*<<2M1^4$XK;99Z'9-MMTNI[&Y!:ZU;L2GZ>M=IK[79+%#<&NFFT
M*36YV(8/WK-C:)JIN'+V&B_3S&LI(F85K!IA",>JHV3J.A;N-RV:S:OSUX]JG]EI7&;00K32"C&\*ZCH[
MNX%FQI-_@/1?)/,:CK.#UL^W.I+MHV3X#N)"79T'N60D(WA/IZG:C=LFJJ5O
M=+QKK9+.LO9=A(EBVF^2>A>0O\4_R1VW0=I?P4]8
MLK1_!%D83W=`RP/QA7J_HBAO.PT]W5*_P]8&GI$#8.ZI7N23?C&O@0N_,$.,
M'&_D'H6#I%3L.\-5W*JZ\ING],P,=#Z;T[5;A!,',I8";-EI?^:MI
MD)>HO9:02<+:FK<=5YIE3]41DO>).Q,,[@^X.OW]`Z]`Z?M^'],4K'C=$:]K
M4O3MW0C)R^=ZY[RCKG'LBK*NY755D!J-M%JU1,4[V2J[IA&W"-;?XC+EB9!F
MB0RSM,`Z]-1T-!+O)(\D`:KV%-1]ZKMSB/,.D-8[&>%3=)6CTWLJMF]1N*G8
MD#2SDXP[29?2T7-&)#VP3)90&Z=?O`/\)?O_`*#_`-^/4/L''XU1LVJW#PVO
M8J@78M']56?K+KR[_`%TXD#)1KN*D5%UG+_7\NY9L2NE5EJY)
M,"+J1"_/,$Q=+]I;V#SK;5Y8M&VM#OI5;X?B6&X@X_>
M8;=72?-KEB[O,.O7?-0S97OH;;K8Q=CBV([06=I"VO^2-WC6#1+
M*.(DZXV!!M7WBIE9)21,TDGFNY5^X,FFK8*[88A8LK09&8,@MFZ3]1)-44G!
MV$FHDN(+'\\0%4S\/#2]`(H,5K_:+O5DJ=4#CKRT(-F9&1U3"ZLH8@B)VQ3I?:;MTT]G639-W.[XJ-9B$C`9X^85^K0RJJ)RB0`&
M2L]FL4T7L^>ZTD/MM/H>8>=D,V]W;8Q9W&0A(1_P"B
MC`\886'B(2DWN)-KG*A;3(0VCC-KOQJS=NBL8H#);%DVOH+F(9'`5@KFN64D"RA
M"@5@U.H+U/(:`0F&D/'M[%),Y:<3;E"4D8]@,4P=/#&,=4S*..Z>JM&I!,"3
M=%9VY6\TF0ZZZBQU##Q7',*%@M+F15J7%!/F5RGS>]GI%;PPY3MQ=6=HG]-#
M*[]UMZ\SBXMV0T76K3V[L+M4K'V5V^]3BR;9M3G^;PQ8Q'`PB66[>R.T3=KA
MV%XUC#I\Y?O&MGK6ZLL&#)P[$+Q5RFUN\4Q\W-PIX=\C9YC:N07%+C=O.S1C
M1./CK'M_1^M-D3[&.2%0R<:UFK=6I:32CBF65$&!77H?^:I_D#VS=;'L>B]*
MW#5:>B[5J36=CTHC$UV!0U#-46LR.L4(.HNHY]589O1',8>KMXFM/(>)(>T,=0\0]H9Q_I:<=.'LX1'R^5>P
MUUNK1LVU"<:*J-9GT5ZCWHV4.@^\^DS:!P:XBTC8\')N9N%O\`4N.NJ*[=(B9>)ND74M&6
MB)JS2:8R;A)\]36?MGJ3I0KMR!E1!8_7*.@:ZH6J*76]<:QI=4UYK^FQ3>"J
M5(I-?BZO4ZQ"M1,+:)@*]"MF<5$QR`G.*31DU12(8YS`7M',(]RZAXA[0QU#
MQ#VAC4]OS]GW'RH`!P`'5H*K&"TGI^KQVQXBMZMU[`1.X;/8KKMB*B*;7V$9
MLRX6]FA'VRT7Z.0CR,;=8+0Q:MF=BEIYN^>3;9NBC)JNB))@6FM;\".#FG+%
M)V_4?#?BOJZUS4+-5N6LVN^/VJ:7/R-=LJ`MK'`.IBN56.?J0D^@(I3<2"Y6
M$JF/8?MUR_8&6?4/$/:&.H>(>T,:^WY^R/\`KY4R@\0#'#0=?'OK"W6_DW_)
M\Z3F871KLAEP,X65Z;\;-1)6]I=&
M\T%D;VUM9"5,)="R(6$`G49M-V613EP"1(X*Z#SN9P]0\0]H8ZAXA[0QK[?$
M?_/E2!V#MX=G"M2!T,/^P_[B?J(_U$1ZC^N;C("#U,/3P+__`%D^#Q]P^@J:
M8QC(I3&,8I3&,8I3&,8I3&,8I3&,8I3&,8I3&,8I3&,8I3&,8I3&,8I00`?O
M#K_7&,8I3&,8I3&,8I3&,8I3&,8I3&,8I3&,8I3&,8I3&,8I7R)0$?P]@_\`
M`AFG8#]/8/S9]YH/_(?$,4KA9:O0,\D1"GCCJ?\WQ^;/,:Q"_8:++%]=LLGBTU<
M/-M&>,MH4$GB9D'K[=?QKS9W9_$;I%[?X%@]]>M06KN\PVRN;IN`$C=W#S*W
M40E*0,JQHD#@!6I$DDR$3("92)E`A"E*!2D*4.@%(4H@4A0```"E`"@'V`&?
M?0OB7]_FR/J?\WQ^;'4_YOC\V>)QXGZ_;Q!]D_L``````"``!```@``=@T'L
MJ3H7Q+^_S8Z%\2_O\V1]3_F^/S8ZG_-\?FQ[_K]O$5E2I64'*I6H0IQ4Y0H@)0A:B3I">V*R
MA`"A^)?^_P!1'/KJ'B'M#(.T;J(=K[A$/Q_#_P#;*JVWL5_KF%K[V-B6DS(V
M6\5BCL49"16BV#1U9G"S=&1>N&[*17,V:&2`RJ*+<55"F_P&`2]DU4(4XI*$
M:J48`F/F8`[^JKNNH9;6ZX2$($J(!48]@2"29Z@*MSJ'B'M#'4/$/:&5AJ^_
M.=@P,E(NXQ&*?0MJLE1?D8R!I:'>O:T_,Q<2,'*"V8G?1+LP=I!51JBJFJ1=
MLJ43HF,-D=3_`&?XOO$`_'\1`/'"T*0HH4(4#!''7V$:'G,5+;B'4)<;,H6`
MI)@@P=1(4`0?80#4_4/$/:&.H>(>T,H/4&W9+:#RT`JRJ<6SKTS/0@1[&U+R
MEL(M"SJ\0B_EX(\0S2C(N42:K.6+D'S@RJA12*F8H"H6]>I_S?L/S9+C:VEE
M"X"A$B9X^T3X]U59>;N&TNM$J;5.4D%,Q[%`$>\"I^H>(>T,=0\0]H91W\V'
MCCMU.(48QII`I9:7;QTLLD[E5/-L(=N5IV'#DRAE5DTTAZW(D=8Z29E.R1
M02$%0A#F4(502%$Y2*""8G(4PB!#BF03E`#"0O7H`MJ2A"U"$N9LAD:A)RDP
M"2`""-1U:5"'FUN.M)5*V"@."",I6@+2)(@RD@Z3QCB"!N^H>(>T,=0\0]H9
M!U/^;X_-CJ?\WQ^;*^_Z_;Q'*=:GZAXA[0QU#Q#VAE<[3O)]:Z\M]["/[X&K
M0CJ7",%T+$'HMS)%!`7?F77F`,*G45`05$`+T`@B/V=?UGLN6NDM`D$K5!DG&J35V[CXQRC)QR)P1E6"SU]W]?FRBJ_MZ2L&X+EK5-E4V#.F/F31=
M9]:ET[9-(OJVA.>FP58"(,D\:L%G"3235-*)E:IF*L`G.8$AJAM2PLI`(;1G
M7J!"9`ZXDRH"!)]U6=?;9+27%$%]P--@`G,LI4J-`0.BE1E4#3C,"K\ZAXA[
M0QU#Q#VAD`"?\WQ^;*MF]CKQ&V*/K0L6FNE<*Y:YY28%X=-1@:M^B@1J1D#<
MY7!7GI(B94SI$4>P'0BG:^PA"EDA.I2E2SK'10G,HZQP`.G$QIU3+CJ&@DK,
M!2VVTZ$RMQ:6T#0'BM:1)T$R2`":MGJ'B'M#'4/$/:&0`8X@`]K[_P"OS94&
MZMHN=45>+L#>.CI-23M]$/6I&&E6B0Q"KP7RRD!.Q+*?J(!!D2""""""9'NFC+S;
M[:76E9VUSE,$<"000H!0(((((!!$$5/U#Q#VACJ'B'M#*./METMN=;4S1E`M
M1CH2(FWKJ>L"\;-S+:62?*&&EPB44[1G"0_HB998SB19&3,N?S1!*W.8UU`8
MXA_J^/S9"VU(RYP!G0E:=092K]ITF)&L'7M$Z5#3S;V\W:LP;<4THP1"T:+&
MH$P=)$@]1(J?J'B'M#'4/$/:&4?N7:[O5R%*%JR@7*EQMR=6%]9[`K6H&$*I
M$R$GWI*2:
MT42\VMUUE))<9R%P00$YTA2=2(,@@Z3'7K7)]0\0]H8ZAXA[0R#J?\WQ^;'4
M_P";X_-E/?\`7[>(Y3K4_4/$/:&.H>(>T,@ZG_-\?FQU/^;X_-CW_7[>(Y2J
M?J'B'M#'4/$/:&0=3_F^/S8ZG_-\?FQ[_K]O$(>T,=0\0]H9!U/^;X_-CJ?\WQ^;'O\`K]O$
MOVF_8
M0Z9)D4IF@_=_N'Q#-L*I^[1S]
M>YH$)(!+K8GJ(=D>PPT1W$UDIQ8)`8=4`?W)+$'AJ,SR5=Z0=#IPFRL96O<6
MU/6%4_=HY^O<=Q;4]853]VCGZ]R=VGTS?<]^+Q'*8WKGJS_Q6_\`(\1RFRL9
M6O<6U/6%4_=HY^O<=Q;4]853]VCGZ]QNT^F;[GOQ>(Y2WKGJS_Q6_P#(\1RF
MRL96O<6U/6%4_=HY^O<=Q;4]853]VCGZ]QNT^F;[GOQ>(Y2WKGJS_P`5O_(\
M1RFRL96O<6U/6%4_=HY^O<=Q;4]853]VCGZ]QNT^F;[GOQ>(Y2WKGJS_`,5O
M_(\1RFRL96O<6U/6%4_=HY^O<=Q;4]853]VCGZ]QNT^F;[GOQ>(Y2WKGJS_Q
M6_\`(\1RFRA^T!#QRKHW5T,SV3;MD.P9RDG9&M5;L4GD.R47KAJRQ=LC+1DH
MH*SDJDF5T!UP2(U%(42E`ZP=!+/W%M3UA5/W:.?KW'<6U/6%4_=HY^O\;E5OT5Y5(S1YQ!A*
MU"#(ZP)"35E?=E8;3UHRVA%5Z'D'XLF<)=:Y;G"7H*;].42@5'!E85PDHN@"
M3>22L*I^[1S]>X4`M16I]HJ4LMDM(0VW:OI0VE*$)SL'*E(`2)-P3`&@DG0'
M_?P^S*V[BVIZPJG[M'/U[CN+:GK"J?NT<_7N%=,(2I]HAM.1`"'`$IF?^+(D
MDDDJ,J)F2=*-_IJ<4BT?"GE[QPEQE14J$IXJN3`"0`$IA*0(2!U[#;VN)+:5
M;4J2-H1KL+)IO&EB24JT78UI-@Z323(5@K)+)A"R3/HL=E)HIN#HJK><\R)T
M4C%L:&BFT'$1<*S%XMJ
M>L*I^[1S]>X[BVIZPJG[M'/U[E-VGTS?<]^+Q'*==ZYZL_\`%;_R/$HB)PZ=!X
M?6FLD-9*6AE#RIU:S/2Z$]&UTT>DW2KDFNP;MI\6#PCA0RL?-/&P2A8\Z"98
MQRLNFW5414Z%W7<6U/6%4_=HY^O<=Q;4]853]VCGZ]RX)#9:%PWNU',4Y72,
MQR:SN9!Z`$@S`4!HHA6)0E3R;@V;V^0D(2YG9!".GT8%S!3^HLD$$$P3)0@B
MR1^X?Z92\#JJ0KVTKAL-E:&JC"[R#%_+UYU5FRKQ$\=7DX%JC&V;O0KAF@8R
M2;UT4(U3TD0%N/8+_FCS_<6U/6%4_=HY^O<=Q;4]853]VCGZ]PCH!82^T`XG
M(L%#BI3F2J.DR8A209$$%.A[9<&]+2EVKY4RX'&R'&4Y5Y2F>CN[9)K-7"JA0<`*X"9,ID^R('$0WO<6U/6%4_=HY^O<=Q;4]853
M]VCGZ]P@;M:5H?:"DF0/6#PY3+IWS:FG+1]2%C*I.=@2-.M-R%#
MF"#IIU3W:$:/6$3'LI%XWD'S5HB@Z>M(XD0U=+)E[)UF\6FX=D8(F_\`QM".
M5R(EZ%*J;[1S@K_5W-UIEEJ3:97KY['$N8927:M4WKAFT?@5!^*#=55$AU7#
M$SAH4QE"@EY\5NAQ3`AN&[BVIZPJG[M'/U[CN+:GK"J?NT<_7N``%A8?:"@H
M*'0<@*!!_;N5J2>/IA/TRL'41B)E*8E'[IX3T6(5[G1BRI@
MS;-4RBU,D0/,9<^5KW%M3UA5/W:.?KW'<6U/6%4_=HY^O<+_`%%9EW#:E0E,
MD.S"0`)(9U@:29,#CPJK4,(W;5FZVC,I61*K?*"M694#SB$@J),)@3,#77@;
M9J9S>/*&B'*C@73N'2;I)N
M%2)I*.#HE`@7.`=`_P"_\96W<6U/6%4_=HY^O<=Q;4]853]VCGZ]R5=,(2I]
MJ&TY4`(<2`)D_M9$DDDE1E1C4G2C8W2G%(M7PIY>=PEQE94J`D:JN50```$I
MA(`,`3KQFV-7K[*+3%6E@2K[ZDVQ.V,%G,`A9&3QTE%OXPC5]&N'\<11MV7Y
MEC!Y_JDA"%/M%*)
MR#*[*_%XCE.N]<]6?^*W_
M`)'B.4V5C*U[BVIZPJG[M'/U[CN+:GK"J?NT<_7N-VGTS?<]^+Q'*6]<]6?^
M*W_D>(Y396,K7N+:GK"J?NT<_7N.XMJ>L*I^[1S]>XW:?3-]SWXO$(Y396,K7N+:GK"J?NT<_7N.XMJ>L*I^[1S]>XW:?3-]SWXO$XMJ>L*I^[1S]>X[BVIZPJG[M'/U[C=I],WW/?B\1RE
MO7/5G_BM_P"1XCE-E8RM>XMJ>L*I^[1S]>Y]$@]H@<@GV#53$`Y1.4NMW)#'
M(!@$Y`/_`!V;L&,3J4I^R;L"(&[)NG9&,B?3-]SWXO$
